Reason for request
Re-assessment of the actual benefit of third-generation oral contraceptives in response to a request by the Directorate-General for Health dated 27 December 2011.
Clinical Benefit
| Insufficient |
taking into account both the increased risk of venous thromboembolic events and the lack of demonstrated benefit in terms of clinical safety in women exposed to third-generation oral contraceptives compared with second- or first-generation oral contraceptives, the actual benefit of these proprietarymedicinal products must be regarded as insufficient for reimbursement by National Health Insurance.
|
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
L8Lq8rhNpfshMBn3